4A
BMRN icon

4Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

4Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
3,906
+26
+0.7% +$1.42K 0.17% 139
2026
Q1 		$213K Buy
3,880
+313
+9% +$18.3K 0.18% 131
2025
Q4 		$212K Buy
+3,567
New +$194K 0.18% 137

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

4Wealth Advisors's BMRN Position: Q2 2026 in Review

4Wealth Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 0.67% in Q2 2026, buying an estimated $1.42K and bringing the position to 3,906 shares worth $225K. The position accounts for 0.17% of the portfolio, ranked #139.

4Wealth Advisors first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. 166 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • 4Wealth Advisors held 3,906 shares of BioMarin Pharmaceuticals worth $225K as of Q2 2026.
  • 4Wealth Advisors bought 26 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.42K.
  • BioMarin Pharmaceuticals made up 0.17% of 4Wealth Advisors's portfolio in Q2 2026, its #139 holding.
  • 4Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 166 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on 4Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.